A carregar...
In Vivo Imaging of Bcr-Abl Overexpressing Tumors with a Radiolabeled Imatinib Analog as an Imaging Surrogate for Imatinib
Imatinib mesylate is a tyrosine kinase inhibitor that was approved by the U.S. Food and Drug Administration in 2001 for treatment of many different stages of chronic myeloid leukemia and in 2002 for treatment of gastrointestinal stromal tumors. Imatinib is known to inhibit the dysregulated prolifera...
Na minha lista:
| Publicado no: | J Nucl Med |
|---|---|
| Main Authors: | , , , , , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
2011
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4429778/ https://ncbi.nlm.nih.gov/pubmed/21764785 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2967/jnumed.110.085050 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|